WallStSmart

Colgate-Palmolive Company (CL)vsMagnera Corp placeholder (MAGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Colgate-Palmolive Company generates 541% more annual revenue ($21.05B vs $3.28B). CL leads profitability with a 9.7% profit margin vs -3.4%. CL appears more attractively valued with a PEG of 1.60. CL earns a higher WallStSmart Score of 54/100 (C-).

CL

Buy

54

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 4.21

MAGN

Hold

44

out of 100

Grade: D

Growth: 6.0Profit: 3.5Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLUndervalued (+12.6%)

Margin of Safety

+12.6%

Fair Value

$99.34

Current Price

$86.80

$12.54 discount

UndervaluedFair: $99.34Overvalued

Intrinsic value data unavailable for MAGN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CL4 strengths · Avg: 9.3/10
Return on EquityProfitability
863.1%10/10

Every $100 of equity generates 863 in profit

Altman Z-ScoreHealth
4.2110/10

Safe zone — low bankruptcy risk

Market CapQuality
$69.19B9/10

Large-cap with strong market position

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

MAGN1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Areas to Watch

CL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
34.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Price/BookValuation
289.3x2/10

Trading at 289.3x book value

MAGN4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$438.24M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.933/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CL

The strongest argument for CL centers on Return on Equity, Altman Z-Score, Market Cap.

Bull Case : MAGN

The strongest argument for MAGN centers on Price/Book.

Bear Case : CL

The primary concerns for CL are PEG Ratio, P/E Ratio, Revenue Growth. Debt-to-equity of 33.29 is elevated, increasing financial risk.

Bear Case : MAGN

The primary concerns for MAGN are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

CL profiles as a value stock while MAGN is a turnaround play — different risk/reward profiles.

CL is growing revenue faster at 4.9% — sustainability is the question.

CL generates stronger free cash flow (867M), providing more financial flexibility.

Monitor HOUSEHOLD & PERSONAL PRODUCTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CL scores higher overall (54/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Colgate-Palmolive Company

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Colgate-Palmolive Company is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. It specializes in the production, distribution and provision of household, health care, personal care and veterinary products.

Visit Website →

Magnera Corp placeholder

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Magnera Corp (MAGN) is a forefront technology firm specializing in advanced data analytics and machine learning solutions, essential for driving digital transformation across multiple industries. With a robust portfolio of proprietary technologies, the company exemplifies a strong commitment to innovation and research and development, ensuring operational efficiency and adaptability in a rapidly evolving market. As Magnera continues to leverage its pioneering capabilities, it represents an appealing investment prospect for institutional investors seeking to engage with transformative growth opportunities within the technology sector.

Want to dig deeper into these stocks?